• A CD19/Fc fusion protein for detection of anti-CD19 chimeric antigen receptors. (escholarship.org)
  • Chimeric Antigen Receptors (CARs) consist of the antigen-recognition portion of a monoclonal antibody fused to an intracellular signaling domain capable of activating T-cells. (escholarship.org)
  • The advent of chimeric antigen receptors has demonstrated promising results in RR-ALL. (nih.gov)
  • Adoptive T-cell therapy with T cells expressing chimeric antigen receptors (CARs) is an active area of cancer research. (ashpublications.org)
  • One way to achieve this is to genetically modify immune cells, mainly T cells and recently also natural killer (NK) cells, to express chimeric antigen receptors (CARs). (nature.com)
  • The ability of the B cell to respond in a specific, yet sensitive manner to the various antigens is achieved with the use of low-affinity antigen receptors. (thermofisher.com)
  • Chimeric antigen receptor T cells (CARTs) are a novel cell-based therapy designed to direct host-derived T-cells against cancer cells through tumor-specific surface receptors. (medpagetoday.com)
  • Chimeric antigen receptors (CARs) endow T cells with antigen-specific recognition, activation, and proliferation independent of major histocompatibility complex ( 1 - 3 ). (snmjournals.org)
  • Of note, CD19, CD20, CD30, CD33, CD123, and CD269 as ideal targets have shown extraordinary potential for CAR-T cell therapy and other targets such as CD23 and SLAMF7 have brought promising future for clinical trials. (hindawi.com)
  • Currently approved CAR-T therapies use CD19 and CD20 as targets. (cancer.org)
  • The objective of this proposal is to improve bispecific anti-CD20/anti-CD19 CAR T-cell activity and persistence by understanding impact of cell manufacturing parameters on final engineered CAR-T product and determining resistance mechanisms in relapsing patients. (lls.org)
  • To address that mechanism of relapse, we initiated a first-in-human trial of dual targeted anti-CD20, anti-CD19 CAR (CAR20.19) T-cells for B-cell malignancies. (lls.org)
  • PHILADELPHIA - Bispecific anti-CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy was well tolerated and showed signs of clinical efficacy in patients with relapsed/refractory B-cell lymphoma, according to phase I clinical trial data presented during Week 1 of the virtual AACR Annual Meeting 2021 , held April 10-15. (aacr.org)
  • In this study, Ghafouri and colleagues evaluated the safety and efficacy of anti-CD19/CD20 bispecific CAR T-cells using naïve memory cells. (aacr.org)
  • The presented analysis included five patients with B-cell malignancies that were positive for both CD19 and CD20 tumor antigen expression. (aacr.org)
  • Naïve memory T cells were extracted from each patient, engineered to express an anti-CD19/CD20 CAR, expanded, and infused back into the patient at one of two different doses (either 5×10 7 cells or 2×10 8 cells). (aacr.org)
  • The patient whose cancer did not respond to treatment had early disease progression with CD19/CD20-negative disease by day 14 after infusion. (aacr.org)
  • Although long-term follow-up and analysis of additional patients are needed, our results indicate that bispecific anti-CD19/CD20 CAR in naïve memory T cells may be safe and effective in patients with relapsed or refractory B-cell lymphomas," Ghafouri said. (aacr.org)
  • We are pleased to have treated the first patient with IMPT-314 and build on the clinical evidence from the ongoing investigator-led study of this dual-targeted CD19/CD20 CAR T-cell therapy. (mystateline.com)
  • We designed this therapy to target both CD19 and CD20 to help restrict antigen escape and ultimately prolong treatment response. (mystateline.com)
  • IMPT-314 is a CD19/CD20-targeting chimeric antigen receptor (CAR) T-cell therapy that utilizes a potent bispecific CAR and a 4-1BB costimulatory domain. (mystateline.com)
  • Clinical trials are in progress assessing the use of mature T-lymphocytes transduced with CARs targeting CD19 antigen to treat B-lineage malignancies. (escholarship.org)
  • CD19 is an attractive target for immunotherapy because of its consistent and specific expression in most of the stages of maturation and malignancies of B-lymphocyte origin, but not on hematopoietic stem cells. (escholarship.org)
  • Adoptive T-cell therapy with anti-CD19 chimeric antigen receptor (CAR)-expressing T cells is a new approach for treating advanced B-cell malignancies. (ashpublications.org)
  • 12 , 13 Clinical trials in which patients with advanced B-cell malignancies receive T cells expressing anti-CD19 CARs are in early stages, and it is not known whether adoptive transfer of T cells targeting this self-antigen will be an effective therapy for B-cell malignancies. (ashpublications.org)
  • Adoptive cell therapy (ACT) with chimeric antigen receptor T (CAR-T) cells can restore the activity of exhausted T cell through reprogramming and is widely used in the treatment of relapsed/refractory (r/r) hematological malignancies. (hindawi.com)
  • Related studies have reported that the complete response rate of CD19-CAR-T cells in hematological malignancies is approximately 88-90% [ 13 , 14 ]. (hindawi.com)
  • CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies. (ajmc.com)
  • Chimeric antigen receptor (CAR) T-cell therapy is an example of how immunotherapy is revolutionizing the treatment of hematologic malignancies with unprecedented response rates in patients with relapsed/refractory lymphoma, multiple myeloma, and acute lymphoblastic leukemia. (ajmc.com)
  • Chimeric antigen receptor T cells for gamma-delta T cell malignancies. (ucl.ac.uk)
  • Successful treatment of B-cell malignancies with CD19-CAR T cells was a milestone for this approach ( 4 , 5 ). (snmjournals.org)
  • The Food and Drug Administration (FDA) has received reports of T-cell malignancies, including chimeric antigen receptor CAR-positive lymphoma, in patients who received treatment with BCMA- or CD19-directed autologous CAR T cell immunotherapies such as idecabtagene vicleucel injection. (medlineplus.gov)
  • Outcomes of CD19-Directed Chimeric Antigen Receptor T Cell Therapy for Transformed Nonfollicular Lymphoma. (moffitt.org)
  • The efficacy of cellular or humoral immunotherapy has been demonstrated with the success of chimeric antigen receptor T-cell therapy and the bispecific engager blinatumomab in treating advanced disease. (haematologica.org)
  • Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. (upenn.edu)
  • Next-Generation Chimeric Antigen Receptor T-Cell Therapy: Going off the Shelf. (upenn.edu)
  • An exception was long-lived CAR-T cells in two adult individuals with a different cancer-chronic lymphocytic leukemia (CLL)-in whom anti-CD19 CAR-T cells have persisted for almost a decade thus far 7 . (nature.com)
  • Previously, we generated a novel low-affinity CAR incorporating a CD19-specific single-chain variable fragment (scFv) called CAT, displaying a faster off-rate of interaction than the FMC63 CD19 binder used in prior clinical studies 3 . (nature.com)
  • ELISA assays using several different monoclonal antibodies to CD19 demonstrated dose-related specific binding by the fusion molecule CD19sIg1-4, but no binding by CD19sIg1-3. (escholarship.org)
  • This fusion molecule is a sensitive reagent for detection of anti-CD19 CAR derived from any monoclonal antibody present in CAR-modified T-cells. (escholarship.org)
  • Cd19 Test (B-lymphocyte antigen CD19, CD19 molecule) in Kasargod at Rs. (bajajfinservhealth.in)
  • B-lymphocyte antigen CD19, also known as CD19 molecule (Cluster of Differentiation 19), B-Lymphocyte Surface Antigen B4, T-Cell Surface Antigen Leu-12 and CVID3 is a transmembrane protein that in humans is encoded by the gene CD19. (wikipedia.org)
  • The CD19 molecule is expressed on 100% of the peripheral B cells as defined by expression of kappa or lambda light chains. (thermofisher.com)
  • The CAR T cells in this clinical trial were also designed to have 2 target antigens: CD19 and CD22. (cancer.net)
  • In recent years, CD22 CAR T cell therapy has emerged as an effective salvage therapy for patients with CD19-negative ALL. (confex.com)
  • In a phase I clinical trial, CD22 CAR T cells were able to induce remission in up to 80% of patients with CD19-negative ALL. (confex.com)
  • Patients achieving remission, who did not undergo a consolidative hematopoietic stem cell transplant, were found to be at high risk of relapse due to downregulation of the CD22 antigen below the threshold required for effective CD22 CAR T cell activity. (confex.com)
  • Thus, strategies to increase the antigen-sensitivity of CD22 CAR T cells have the potential to enhance the induction and duration of remission in ALL patients. (confex.com)
  • As the properties of a CAR that influence sensitivity to antigen are not well defined, we began by testing the impact of increasing the affinity of the single-chain fragment variable (scFv) for the CD22 antigen. (confex.com)
  • CARs displayed on the surface of transduced cells perform non-MHC-restricted antigen recognition and activating intracellular signaling pathways for induction of target cytolysis, cytokine secretion and proliferation. (escholarship.org)
  • These fusion proteins are intended to work in similar fashion as the MHC Tetramers used for identification of antigen-specific T-cells, and may also have other applications in studies of activation of anti-CD19 CAR bearing cells. (escholarship.org)
  • Conjugation of the CD19sIg1-4 fusion protein to Alexa Fluor 488 allowed specific and sensitive staining of anti-CD19 CAR-bearing cells for flow cytometry assays, detecting as low as 0.5% of CAR-modified primary cells with minimal background staining. (escholarship.org)
  • In the context of relapsed and refractory childhood pre-B cell acute lymphoblastic leukemia (R/R B-ALL), CD19-targeting chimeric antigen receptor (CAR)-T cells often induce durable remissions, which requires the persistence of CAR-T cells. (nature.com)
  • In this study, we systematically analyzed CD19 CAR-T cells of 10 children with R/R B-ALL enrolled in the CARPALL trial via high-throughput single-cell gene expression and T cell receptor sequencing of infusion products and serial blood and bone marrow samples up to 5 years after infusion. (nature.com)
  • These findings raise the possibility that a universal transcriptional signature of clinically effective, persistent CD19 CAR-T cells exists. (nature.com)
  • B-lineage acute lymphoblastic leukemia (B-ALL) is the most common type of childhood cancer and mostly derives from immature B cells that carry the cell surface antigen CD19 (ref. 1 ). (nature.com)
  • Although a subset of children can be cured, up to 60% of children experience further, typically fatal, disease recurrence due to non-persistence of CAR-T cells or CD19 − leukemic escape 3 , 4 . (nature.com)
  • We studied 15 consecutive patients with high-risk or relapsed CD19 + B-ALL treated with CD19 CAR-T cell therapy on the CARPALL study ( NCT02443831 ) and in whom adequate CAR-T cells could be isolated for subsequent analyses from cryopreserved samples of blood or bone marrow. (nature.com)
  • Chimeric antigen receptor-modified T cells (CAR-T) and engineered T cells are used to target cancer cells. (nih.gov)
  • Plasma cells do not express CD19. (biolegend.com)
  • We designed a lentiviral vector expressing a chimeric antigen receptor with specificity for the B-cell antigen CD19, coupled with CD137 (a costimulatory receptor in T cells [4-1BB]) and CD3-zeta (a signal-transduction component of the T-cell antigen receptor) signaling domains. (nih.gov)
  • A low dose (approximately 1.5×10(5) cells per kilogram of body weight) of autologous chimeric antigen receptor-modified T cells reinfused into a patient with refractory chronic lymphocytic leukemia (CLL) expanded to a level that was more than 1000 times as high as the initial engraftment level in vivo, with delayed development of the tumor lysis syndrome and with complete remission. (nih.gov)
  • Apart from the tumor lysis syndrome, the only other grade 3/4 toxic effect related to chimeric antigen receptor T cells was lymphopenia. (nih.gov)
  • Engineered cells persisted at high levels for 6 months in the blood and bone marrow and continued to express the chimeric antigen receptor. (nih.gov)
  • A specific immune response was detected in the bone marrow, accompanied by loss of normal B cells and leukemia cells that express CD19. (nih.gov)
  • To evaluate anti-CD19-CAR-transduced T cells in a murine model of adoptive T-cell therapy, we developed a CAR that specifically recognized murine CD19. (ashpublications.org)
  • We used T cells that were retrovirally transduced with this CAR to treat mice bearing a syngeneic lymphoma that naturally expressed the self-antigen murine CD19. (ashpublications.org)
  • One infusion of anti-CD19-CAR-transduced T cells completely eliminated normal B cells from mice for at least 143 days. (ashpublications.org)
  • Anti-CD19-CAR-transduced T cells eradicated intraperitoneally injected lymphoma cells and large subcutaneous lymphoma masses. (ashpublications.org)
  • The antilymphoma efficacy of anti-CD19-CAR-transduced T cells was critically dependent on irradiation of mice before anti-CD19-CAR-transduced T-cell infusion. (ashpublications.org)
  • Anti-CD19-CAR-transduced T cells had superior antilymphoma efficacy compared with the anti-CD19 monoclonal antibody from which the anti-CD19 CAR was derived. (ashpublications.org)
  • Our results demonstrated impressive antilymphoma activity and profound destruction of normal B cells caused by anti-CD19-CAR-transduced T cells in a clinically relevant murine model. (ashpublications.org)
  • Most CARs that are being evaluated in current clinical and preclinical studies recognize self-antigens that are expressed by normal tissues as well as malignant cells. (ashpublications.org)
  • CD19 expression is restricted to normal mature B cells, malignant B cells, and B-cell precursors. (ashpublications.org)
  • 1 In addition, the optimal approach to treating patients with anti-CD19-CAR-expressing T cells is not known. (ashpublications.org)
  • To establish a murine model in which a completely syngeneic lymphoma could be treated by adoptive transfer of syngeneic CAR-transduced T cells, we developed a CAR that could specifically recognize murine CD19. (ashpublications.org)
  • In humans, CD19 is expressed in all B lineage cells. (wikipedia.org)
  • Contrary to some early doubts, human plasma cells do express CD19, as confirmed by others. (wikipedia.org)
  • CD19 is widely expressed during all phases of B cell development until terminal differentiation into plasma cells. (wikipedia.org)
  • CD19 expression in mature B cells is threefold higher than that in immature B cells. (wikipedia.org)
  • CD19 is expressed on all normal, mitogen-stimulated, and malignant B cells, excluding plasma cells[inconsistent]. (wikipedia.org)
  • CD19 expression is even maintained in B lineage cells that undergo neoplastic transformation. (wikipedia.org)
  • Experiments using CD19 knockout mice found that CD19 is essential for B cell differentiative events including the formation of B-1, germinal center, and marginal zone (MZ) B cells. (wikipedia.org)
  • Analysis of mixed bone marrow chimeras suggest that prior to an initial antigen encounter, CD19 promotes the survival of naive recirculating B cells and increases the in vivo life span of B cells in the peripheral B cell compartment. (wikipedia.org)
  • Using a loss of function approach, researchers found reduced MYC levels in B cells of CD19 knockdown mice. (wikipedia.org)
  • The Akt-GSK3β axis is necessary for MYC activation by CD19 in BCR-negative cells, with higher levels of Akt activation corresponding to higher levels of MYC. (wikipedia.org)
  • CD19 is a crucial BCR-independent regulator of MYC-driven neoplastic growth in B cells since the CD19-MYC axis promotes cell expansion in vitro and in vivo. (wikipedia.org)
  • CAR-expression on T or NK cells allows them to specifically target cancer cells via recognition of tumor associated antigens. (nature.com)
  • The addition of separate adapter molecules (AMs) specific for tumor antigens and CAR-immune cells targeting these AMs allows a more precise and temporally limited therapy. (nature.com)
  • Yet, if and how the tissue environment shapes the antigen specificity of iNKT cells remains unknown. (elifesciences.org)
  • By analysing iNKT cells from lymphoid tissues of mice and humans we demonstrate that their T cell receptor (TCR) repertoire is highly diverse and is distinct for cells from various tissues resulting in differential lipid-antigen recognition. (elifesciences.org)
  • This suggests that unique tissue-specific factors (including local lipid antigens, cytokines and/or hormones) may shape the population of iNKT cells resident in those tissues, ultimately regulating local immune responses. (elifesciences.org)
  • iNKT cells have been traditionally defined by the expression of an invariant TCR α-chain (Vα14-Jα18 in mice or Vα24-Jα18 in humans) and their capacity to recognise the glycolipid antigen α-galactosylceramide (αGalCer) presented on CD1d. (elifesciences.org)
  • Flow cytometry analysis of CD19 was performed by staining Raji CD19 Knock out cells with 0.25 µg Mouse IgG1 kappa Isotype Control (P3.6.2.8.1), PE, eBioscience™ (Product # 12-4714-82, yellow histogram) or 0.25 µg CD19 Monoclonal Antibody (HIB19), PE, eBioscience™ (Product # 12-0199-42, blue histogram). (thermofisher.com)
  • CD19 is expressed by B cells during all stages of development excluding the terminally differentiated plasma cells. (thermofisher.com)
  • Follicular dendritic cells also express CD19. (thermofisher.com)
  • Signaling through CD19 induces tyrosine phosphorylation, calcium flux and proliferation of B cells. (thermofisher.com)
  • CD19 appears to be expressed on myeloid leukemia cells, particularly those of monocytic lineage. (thermofisher.com)
  • Blinatumomab is a bispecific T-cell engager (BiTE) targeting CD19 on malignant B cells and CD3 on normal host T cells. (hindawi.com)
  • Chimeric Antigen Receptor (CAR) modified T-cells are an exciting new form of immunotherapy that involves the genetic modification of one's own T-cells to redirect them against proteins on cancer cells. (lls.org)
  • This therapy is most advanced in blood cancers, specifically B-cell lymphomas and leukemias, with multiple FDA approved CAR T-cells treatments targeting the CD19 protein now available. (lls.org)
  • One proposed mechanism to explain the failure of single targeted CD19 CAR T-cell therapy is that tumors escape CAR T-cells by ridding itself of the CD19 protein. (lls.org)
  • We hypothesized that targeting multiple antigens on tumor cells could be a more effective approach to minimize tumor antigen escape. (lls.org)
  • Other CAR T cells usually only target 1 antigen. (cancer.net)
  • Those 2 products attack the target antigen CD19, but in some patients, relapse occurs when the lymphoma cells stop producing CD19. (ajmc.com)
  • This second-generation of CAR T targets an alternative surface marker called B cell activating factor receptor (BAFF-R). Scientists engineered CAR T cells to go after human lymphoma and acute lymphocytic leukemia cells expressing BAFF-R in vitro and in mouse models in comparison with CD19-directed CAR T cells. (ajmc.com)
  • The BAFF-R-CAR T cells also killed CD19-negative tumor cells isolated from 4 patients with leukemia who relapsed after being treated with a CD19-targeting antibody, and extended survival in mice that were implanted with cells from a fifth relapsed patient. (ajmc.com)
  • In addition, the BAFF-R-directed CAR T cells targeted CRISPR-modified human leukemia cells that lacked CD19. (ajmc.com)
  • Bispecific CAR T cells target two tumor antigens at once and have been explored as a strategy to reduce the risk of relapse. (aacr.org)
  • Ruella M, Kenderian SS, Shestova O, Klichinsky M, Melenhorst JJ, Wasik MA, Lacey SF, June CH, and Gill S. A Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells (CART) for B cell neoplasms . (upenn.edu)
  • The Addition of the BTK inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma. (upenn.edu)
  • These strategies rely on the isolation of T cells, which are either genetically modified to target tumor-specific antigens or are expanded from an endogenous population that recognizes tumor neoantigens. (aacr.org)
  • To improve this therapeutic strategy, Rosenberg and colleagues developed a method to identify the exact antigens that the T cells could recognize. (aacr.org)
  • Chimeric antigen receptor (CAR) T-cell therapy is designed to enhance the body's immune system to effectively kill malignant cells. (ajmc.com)
  • There remains an urgent need for the noninvasive tracking of transfused chimeric antigen receptor (CAR) T cells to determine their biodistribution, viability, expansion, and antitumor functionality. (snmjournals.org)
  • The first phase of in vitro experiments successfully synthesized and expressed in transfected cells the chimeric antigen receptor (CAR) construct targeting CD19 and NR2F6. (kdvr.com)
  • CD19 directed CAR T cells have demonstrated the ability to induce complete remissions in up to 90% of r/r ALL patients. (confex.com)
  • A major mechanism for relapse after CD19-directed CAR T cell therapy is the recurrence of antigen-negative ALL cells. (confex.com)
  • Anti-CD19 CAR T-cell therapy has revolutionized the management of this disease in recent years, but it still has several limitations," she noted, explaining that approximately half of patients relapse within six months of starting the treatment due to a lack of CAR T-cell persistence and/or downregulation of the target antigen, CD19, on the tumor. (aacr.org)
  • Sarah Larson , M.D. principal investigator and associate clinical professor of medicine, David Geffen School of Medicine at University of California, Los Angeles added, "While CD19 CAR T-cell therapies have transformed the lymphoma treatment landscape, durability has been limited by treatment resistance due to selective pressure against the target antigen and subsequent loss of expression. (mystateline.com)
  • Results from a recent study from China showed that a new approach to chimeric antigen receptor (CAR) T-cell therapy was able to put B-cell acute lymphoblastic leukemia (ALL) into remission in many children with high-risk disease. (cancer.net)
  • Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia. (ucl.ac.uk)
  • The advent of chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of relapsed/refractory acute lymphoblastic leukemia (r/r ALL). (confex.com)
  • GC012F is an autologous CAR-T therapeutic candidate dual-targeting B cell maturation antigen (BCMA) and CD19, and utilizes Gracell's proprietary FasTCAR next-day manufacturing platform. (biospace.com)
  • Researchers said Wednesday they created a second-generation chimeric antigen receptor (CAR) T-cell therapy that prevented relapse of lymphoma and leukemia and led to 100% long-term survival in early laboratory studies. (ajmc.com)
  • GC012F simultaneously targets CD19 and BCMA to drive fast, deep and durable responses, which can potentially improve efficacy and reduce relapse in multiple myeloma and B-NHL patients. (biospace.com)
  • CD19, in association with CD21 and CD81, forms a molecular complex integral to B cell activation. (biolegend.com)
  • CD19 forms a complex with CD21 (CR2) and CD81 (TAPA-1), and functions as a BCR co-receptor. (biolegend.com)
  • on the other, it works within the CD19/CD21 complex to decrease the threshold for B cell receptor signaling pathways. (wikipedia.org)
  • On the cell surface, CD19 is the dominant signaling component of a multimolecular complex including CD21, a complement receptor, CD81, a tetraspanin membrane protein (TAPA-1), and CD225. (wikipedia.org)
  • Research has intensified to understand ERV protein function and their role as tumor antigens and targets for cancer (immune) therapy. (frontiersin.org)
  • This medication targets CD19 which is a b-cell lymphocyte antigen that is present in some cancers. (oncolink.org)
  • In this systematic review, we discuss the efficacy and safety of CD19-specific CAR-T therapy in RR-B-cell ALL in the pediatric and young adult population. (nih.gov)
  • We believe GC012F has vast potential to meaningfully improve cancer care, including the faster delivery to patients enabled by Gracell's FasTCAR next-day manufacturing and a novel approach of BCMA and CD19 dual-targeting in multiple indications. (biospace.com)
  • GC012F is a FasTCAR-enabled BCMA/CD19 dual-targeting CAR-T product candidate that is currently being evaluated in IIT studies in China for the treatment of multiple myeloma and B-cell non-Hodgkin's lymphoma. (biospace.com)
  • Our subgroup analysis shows the incidence rate of minimal residual negative complete remission was 69% with the CD28z costimulatory domain, 81% with the 4-1BB domain, and 77% with fourth-generation CD19-specific CAR-T therapy. (nih.gov)
  • For those with relapsed aggressive B-cell lymphoma, anti-CD19 CAR T-cell therapy can achieve a long-term remission in 30-40% of patients. (lls.org)
  • [ 2 ] Options for second-line therapy in patients with relapsed/refractory disease include chemotherapy-free regimens with biologic targeted agents such as covalent Bruton tyrosine kinase (BTK) inhibitors, lenalidomide,venetoclax, and chimeric antigen receptor (CAR) T-cell therapy. (medscape.com)
  • Chimeric antigen receptor (CAR) T-cell therapy can induce durable remissions and possibly cure patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) with poor prognosis and no standard therapeutic options. (medpagetoday.com)
  • CD19 is involved in B cell development, activation, and differentiation. (biolegend.com)
  • The presence of a functional BCR is necessary during antigen-dependent differentiation and for continued survival in the peripheral immune system. (wikipedia.org)
  • Part of B cell differentiation is controlling c-MYC protein stability and steady-state levels through CD19, which acts as a PAX5 target and downstream effector of the PI3K-AKT-GSK3β axis. (wikipedia.org)
  • CD19 is a 95 kd Type I transmembrane glycoprotein in the immunoglobulin superfamily (IgSF) with two extracellular C2-set Ig-like domains and a relatively large, 240 amino acid, cytoplasmic tail that is highly conserved among mammalian species. (wikipedia.org)
  • During B cell lymphopoiesis, CD19 surface expression starts during immunoglobulin (Ig) gene rearrangement, which coincides during B lineage commitment from hematopoietic stem cell. (wikipedia.org)
  • The most active T cell endogenous inhibitory pathway is the immunoglobulin superfamily such as CD28/cytotoxic T lymphocyte antigen-4 (CTLA-4): B7-1/B7-2 receptor/ligand grouping, which plays a central role in coordinating immune responses [ 7 , 8 ]. (hindawi.com)
  • CD19 is a member of the immunoglobulin superfamily and has two Ig like domains. (thermofisher.com)
  • The receptor for CD19 is an important functional regulator of normal and malignant B cell proliferation, and is expressed in all B cell precursor leukemias. (thermofisher.com)
  • C57BL/6 mouse splenocytes were stained with CD19 (clone 6D5) PE/Dazzle™ 594 (filled histogram) or rat IgG2a, κ PE/Dazzle™ 594 isotype control (open histogram). (biolegend.com)
  • A two-parameter pseudocolor density plots showing the correlated expression of CD19 (or Ig Isotype control staining) versus side light-scatter (SSC) signals was derived from gated events with the forward and side light-scatter characteristics of intact leucocytes. (bdbiosciences.com)
  • Chimeric antigen receptor (CAR)-T cell therapies are on the verge of becoming powerful immunotherapeutic tools for combating hematological diseases confronted with pressing medical needs. (nature.com)
  • Despite various approved therapies available, including CD19-targeted CAR T-cell therapies, there remains a significant unmet need for safe and highly efficacious therapies for B-cell lymphomas. (mystateline.com)
  • The advent of CD19 chimeric antigen receptor (CAR)-T cell therapy in recent years has transformed the treatment of intractable ALL 2 . (nature.com)
  • In 2017, the US Food and Drug Administration approved CD19-specific CAR-T (tisagenlecleucel) therapy for RR-B-cell ALL in patients under 25 years old. (nih.gov)
  • Besides modification based on a second-generation CAR, more advanced CAR-immune cell therapeutics are being tested, which utilize precise insertion of genes to circumvent graft-versus-host disease (GvHD) or employ a dual targeting approach and adapter CARs in order to avoid therapy resistance caused by antigen loss. (nature.com)
  • Thereby, several antigens can be targeted at once and the therapy can be adapted in case antigen-loss tumor variants appear. (nature.com)
  • Adoptive cellular therapy, especially chimeric antigen receptor (CAR) T cell therapy, has gained unprecedented success among hematologic tumors [ 11 ]. (hindawi.com)
  • Kymriah is the first CAR-T therapy based on CD19 approved by the FDA in 2017 [ 12 ]. (hindawi.com)
  • Several types of ACT round out the immunotherapy arsenal, including chimeric antigen receptor (CAR) T-cell therapy, T-cell receptor (TCR) therapy, and tumor-infiltrating lymphocyte (TIL) therapy. (aacr.org)
  • 204. Prior CD19 targeted therapy with the exception of subjects who received KTE-X19 or axicabtagene ciloleucel in this study and are eligible for re-treatment. (who.int)
  • 205. Prior chimeric antigen receptor therapy or other genetically modified T cell therapy 206. (who.int)
  • Furthermore, the so-called adapter CARs have been developed by splitting antigen recognition and CAR-immune cell activation. (nature.com)
  • Despite this prototypical TCR repertoire gene usage, in recent years it has become apparent that there are variations within the iNKT cell repertoire that ultimately impact the antigen recognition capacity and consequently the functional outcomes during an immune response. (elifesciences.org)
  • A specific reagent for the detection of anti-CD19 CAR expression was developed, a fusion protein consisting of human CD19 extracellular domains and the Fc region of human IgG1 (CD19sIg). (escholarship.org)
  • This assessment can also be done by measuring antibody responses following active immunization with protein or polysaccharide antigens. (medscape.com)
  • In children who have completed immunizations with diphtheria, pertussis, and tetanus (DPT) or Hib-conjugated vaccines, the antibody response to protein antigens can be tested in adults and older children by measuring IgG antibodies to tetanus or diphtheria toxoid and H influenzae type b (Hib) polysaccharide antigen. (medscape.com)
  • Assessment of responses to polysaccharide antigens is important in patients older than 18-24 months because these responses may be deficient in some patients who can respond normally to protein antigens. (medscape.com)
  • Therefore, antibody responses should be measured to polysaccharide antigens that are not present in the protein-conjugated pneumococcal vaccine. (medscape.com)
  • CD19 signaling, independent of BCR functions, increases c-MYC protein stability. (wikipedia.org)
  • CD19 signaling involves the recruitment and activation of phosphoinositide 3-kinase (PI3K) and later downstream, the activation of protein kinase B (Akt). (wikipedia.org)
  • We hypothesized that this approach might increase CAR T-cell persistence and expansion in the patient, while limiting relapses due to loss of the tumor antigen. (aacr.org)
  • CD19 is a 95 kD glycoprotein also known as B4. (biolegend.com)
  • Description: The HIB19 monoclonal antibody reacts with human CD19, a 95 kDa transmembrane glycoprotein. (thermofisher.com)
  • Ultimately, CD19 expression is integral to the propagation of BCR-induced survival signals and the maintenance of homeostasis through tonic signaling. (wikipedia.org)
  • This persistence signature was also detected in two adult patients with chronic lymphocytic leukemia with decade-long remissions who received a different CD19 CAR-T cell product. (nature.com)
  • Binding of a tumor antigen via the scFv activates the T cell in a major histocompatibility-independent manner which leads to a cytotoxic response [ 3 ]. (nature.com)
  • Leukemia phenotype studies have demonstrated that the earliest and broadest B cell restricted antigen is the CD19 antigen. (thermofisher.com)
  • I have been diagnosed with High Grade (CD19, 20, 22 and Max 5 affected) Large B Cell Non Hodgkin Lymphoma (Dx Jan 16th 2017). (cancer.org)
  • Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. (ucl.ac.uk)
  • This Antibody was verified by Knockout to ensure that the antibody binds to the antigen stated. (thermofisher.com)
  • Knockout of CD19 was achieved by CRISPR-Cas9 genome editing using LentiArray™ Lentiviral sgRNA (Product # A32042, Assay ID CRISPR807388_LV) and LentiArray Cas9 Lentivirus (Product # A32064). (thermofisher.com)
  • A total of 448 patients received a CD19-specific CAR-T product, and 446 patients had evaluable data. (nih.gov)
  • Notably, among patients who relapsed after CAR20.19 treatment, CD19 loss was not identified, suggesting that dual antigen targeting may inhibit the mechanism of antigen escape. (lls.org)
  • In humans, CD19 is encoded by the 7.41 kilobase CD19 gene located on the short arm of chromosome 16. (wikipedia.org)
  • The application of antigen receptor gene rearrangement of BIOMED-2 in the pathologic diagnosis of 348 cases with non-Hodgkin lymphoma in a single institution in Southwest of China. (cdc.gov)
  • The following product was used in this experiment: CD19 Monoclonal Antibody (HIB19), PE, eBioscience™ from Thermo Fisher Scientific, catalog # 12-0199-42, RRID AB_1834376. (thermofisher.com)